Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sibanye Stillwater Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.69 (market cap $39.89B), while Sibanye Stillwater Ltd trades at $8.47 (market cap $5.95B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.7× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.64% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SBSW | |
|---|---|---|
Market Cap | $39.89B | $5.95B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $21.12 |
52-Week Low | $278.09 | $7.27 |
Enterprise Value | $38.15B | $7.57B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Sibanye Stillwater (SBSW) trades at $8.55, down 0.12% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.30 billion in 2024, though revenue stabilized at $112.13 billion. Recent news highlights a potential turnaround with EBITDA growth and debt reduction plans, while analyst consensus is mixed with 42.9% buy ratings.
The outlook hinges on operational improvements and commodity price recovery. Key risks include persistent negative margins and high debt levels, but low valuation multiples may attract value investors if the company executes its turnaround strategy effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
